The rapid expansion of knowledge and treatment options for atopic dermatitis (AD) has created both opportunities and challenges for clinicians. In an interview with Dermatology Times, Jonathan Silverberg, MD, PhD, MPH, highlighted the need for a focused platform to help clinicians keep pace with these advancements. “RAD was created to address this amazing increase in knowledge and treatment options that we have now for atopic dermatitis,” said Silverberg. “It’s hard for the clinician who’s busy in the trenches to keep up with all the data and to really gain insights into all these new therapies that kind of hit us at once, and are still coming really fast and furious.”
Introducing New Approvals and Practical Insights
Silverberg, a professor of dermatology and director of clinical research and contact dermatitis at the George Washington University School of Medicine and Health Sciences, is the founder of the Revolutionizing Atopic Dermatitis (RAD) conference. He recently presented on new AD approvals for practicing clinicians, focusing on recently approved biologics nemolizumab and lebrikizumab. His presentation emphasized their mechanisms of action, clinical utility, and practical tips for integrating these therapies into patient care.
Advancing the AD Treatment Landscape
While established treatments like dupilumab and oral JAK inhibitors continue to evolve, Silverberg stressed the importance of ongoing data in refining patient selection and long-term safety monitoring. He also highlighted the rapid expansion of the AD pipeline, including bispecific and multispecific biologics designed to target multiple immune pathways without increasing off-target effects. Promising investigational targets such as OX40/OX40L, IL-18, and IL-22 receptor pathways represent novel therapeutic avenues with the potential to serve distinct patient endotypes.
Addressing Gaps in Diagnostics and Biomarkers
Silverberg identified a critical gap in the management of chronic inflammatory dermatoses: the need for better diagnostics and predictive biomarkers. Current classification systems are outdated and insufficient for making precise, personalized treatment decisions. Enhanced theranostic tools could significantly improve how dermatologists stratify disease, track response, and forecast prognosis.
The Role of RAD in Clinical Practice
The RAD conference was established to help dermatologists navigate the overwhelming pace of new data and therapeutic options in AD. For clinicians managing complex cases in busy clinics, RAD serves as a focused, evidence-based forum to stay current, refine treatment algorithms, and gain insights directly from colleagues. “RAD is totally rad,” Silverberg noted, describing it as a platform that not only celebrates the science but also provides clinicians with the clarity and confidence to navigate this new era in AD care.
Related topics:
- Dr. Mittendorf Has Drawn a Multi-Dimensional Blueprint for the Development of ASCO
- Medical Breakthrough: FCPANP25 Conference Focuses on New Directions in the Treatment of Chronic Hand Eczema
- Recludix Pharma Makes a Major Announcement: The New STAT6 Inhibitor REX-8756 Initiates a New Journey in the Treatment of type 2 Inflammatory Diseases
